American International Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-27,804
| Closed | -$958K | – | 3179 |
|
|
2020
Q3 | $958K | Sell |
27,804
-633
| -2% | -$13.5K | ﹤0.01% | 1267 |
|
|
2020
Q2 | $475K | Buy |
28,437
+1,796
| +7% | +$30.5K | ﹤0.01% | 1621 |
|
|
2020
Q1 | $384K | Sell |
26,641
-1,538
| -5% | -$39.3K | ﹤0.01% | 1556 |
|
|
2019
Q4 | $943K | Buy |
28,179
+124
| +0.4% | +$3.47K | ﹤0.01% | 1364 |
|
|
2019
Q3 | $587K | Sell |
28,055
-194
| -0.7% | -$3.96K | ﹤0.01% | 1573 |
|
|
2019
Q2 | $588K | Buy |
28,249
+334
| +1% | +$6.88K | ﹤0.01% | 1615 |
|
|
2019
Q1 | $624K | Sell |
27,915
-905
| -3% | -$21.3K | ﹤0.01% | 1578 |
|
|
2018
Q4 | $689K | Buy |
28,820
+92
| +0.3% | +$2.38K | ﹤0.01% | 1487 |
|
|
2018
Q3 | $784K | Buy |
28,728
+517
| +2% | +$14.6K | ﹤0.01% | 1601 |
|
|
2018
Q2 | $759K | Buy |
28,211
+5,485
| +24% | +$168K | ﹤0.01% | 1565 |
|
|
2018
Q1 | $723K | Sell |
22,726
-978
| -4% | -$34.4K | ﹤0.01% | 1469 |
|
|
2017
Q4 | $896K | Buy |
23,704
+113
| +0.5% | +$3.65K | ﹤0.01% | 1430 |
|
|
2017
Q3 | $585K | Buy |
23,591
+1,764
| +8% | +$38K | ﹤0.01% | 1661 |
|
|
2017
Q2 | $449K | Buy |
21,827
+5,643
| +35% | +$108K | ﹤0.01% | 1779 |
|
|
2017
Q1 | $352K | Buy |
16,184
+1,070
| +7% | +$21.9K | ﹤0.01% | 1847 |
|
|
2016
Q4 | $309K | Sell |
15,114
-40
| -0.3% | -$818 | ﹤0.01% | 1927 |
|
|
2016
Q3 | $227K | Buy |
15,154
+23
| +0.2% | +$310 | ﹤0.01% | 2078 |
|
|
2016
Q2 | $164K | Buy |
15,131
+8,711
| +136% | +$118K | ﹤0.01% | 2275 |
|
|
2016
Q1 | $87K | Buy |
+6,420
| New | +$100K | ﹤0.01% | 3534 |
|
American International Group's AIMT Position: Q4 2020 in Review
American International Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 27,804 shares — an estimated $958K sold.
American International Group first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $958K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- American International Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- American International Group sold 27,804 Aimmune Therapeutics shares in Q4 2020, an estimated $958K.
- American International Group first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
- American International Group's Aimmune Therapeutics position peaked at $958K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on American International Group's 13F filing for Q4 2020, filed 12 Feb 2021.